Artificial Cornea and Corneal Implant Market

Executive Summary

Artificial Cornea and Corneal Implant Market was valued at US $452.51 million in 2021 and is projected to grow at 8.26% CAGR over the forecast period to reach US $728.34 million by 2027. Artificial Cornea and Corneal Implant Market represented US $66.39 million opportunity over 2019-2021 and estimated to create US $275.83 million opportunity in 2027 over 2021.

Artificial Cornea and Corneal Implant from Consainsights analyses the Artificial Cornea and Corneal Implant Market in the Life Sciences industry over the forecast period to 2027.

Artificial Cornea and Corneal Implant research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Artificial Cornea and Corneal Implant segmentation includes Type, Transplant Type, Disease Indication, End-user, Region and Geography.

Based on the Type, the Artificial Cornea and Corneal Implant analysis covers Human Cornea, Artificial Cornea.

In Type segment, Human Cornea segment has highest cagr growth of 7.31%.

Based on the Transplant Type, the Artificial Cornea and Corneal Implant analysis covers Penetrating Keratoplasty, Endothelial Keratoplasty, Other Transplants.

In Transplant Type segment, Penetrating Keratoplasty segment has highest cagr growth of 7.31%.

Based on the Disease Indication, the Artificial Cornea and Corneal Implant analysis covers Fuchs’ Dystrophy, Fungal Keratitis, Keratoconus, Other Diseases.

In Disease Indication segment, Fuchs’ Dystrophy segment has highest cagr growth of 7.31%.

Based on the End-user, the Artificial Cornea and Corneal Implant analysis covers Impact of COVID-19 on the End-User Market, Hospitals, Specialty Clinics & Ambulatory Surgery Centers.

In End-user segment, Impact of COVID-19 on the End-User Market segment has highest cagr growth of 7.31%.

Based on the Region, the Artificial Cornea and Corneal Implant analysis covers North America, Europe, Asia-Pacific, Latin America, Middle East & Africa.

In Region segment, North America segment has highest cagr growth of 7.31%.

Based on the region, the Artificial Cornea and Corneal Implant analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Type

Introduction

In 2021, Artificial Cornea segment has the highest revenue of US $266.20 million and is expected to grow at CAGR of 7.31% by 2027 Human Cornea segment has highest cagr growth of 7.31%.

Human Cornea

Human Cornea segment was valued at US $158.97 million in 2019 and is projected to grow at 7.31% CAGR over the forecast period to reach US $299.87 million by 2027. Human Cornea segment represented US $27.33 million opportunity over 2019-2021 and estimated to create US $113.57 million opportunity in 2027 over 2021.

Artificial Cornea

Artificial Cornea segment was valued at US $227.15 million in 2019 and is projected to grow at 7.31% CAGR over the forecast period to reach US $428.47 million by 2027. Artificial Cornea segment represented US $39.05 million opportunity over 2019-2021 and estimated to create US $162.27 million opportunity in 2027 over 2021.

Transplant Type

Introduction

In 2021, Penetrating Keratoplasty segment has the highest revenue of US $299.29 million and is expected to grow at CAGR of 7.31% by 2027 Penetrating Keratoplasty segment has highest cagr growth of 7.31%.

Penetrating Keratoplasty

Penetrating Keratoplasty segment was valued at US $255.38 million in 2019 and is projected to grow at 7.31% CAGR over the forecast period to reach US $481.73 million by 2027. Penetrating Keratoplasty segment represented US $43.91 million opportunity over 2019-2021 and estimated to create US $182.44 million opportunity in 2027 over 2021.

Endothelial Keratoplasty

Endothelial Keratoplasty segment was valued at US $129.36 million in 2019 and is projected to grow at 7.31% CAGR over the forecast period to reach US $244.00 million by 2027. Endothelial Keratoplasty segment represented US $22.24 million opportunity over 2019-2021 and estimated to create US $92.41 million opportunity in 2027 over 2021.

Other Transplants

Other Transplants segment was valued at US $1.38 million in 2019 and is projected to grow at 7.31% CAGR over the forecast period to reach US $2.61 million by 2027. Other Transplants segment represented US $0.24 million opportunity over 2019-2021 and estimated to create US $0.99 million opportunity in 2027 over 2021.

Disease Indication

Introduction

In 2021, Fuchs’ Dystrophy segment has the highest revenue of US $192.52 million and is expected to grow at CAGR of 7.31% by 2027 Fuchs’ Dystrophy segment has highest cagr growth of 7.31%.

Fuchs’ Dystrophy

Fuchs’ Dystrophy segment was valued at US $164.28 million in 2019 and is projected to grow at 7.31% CAGR over the forecast period to reach US $309.88 million by 2027. Fuchs’ Dystrophy segment represented US $28.24 million opportunity over 2019-2021 and estimated to create US $117.35 million opportunity in 2027 over 2021.

Fungal Keratitis

Fungal Keratitis segment was valued at US $125.51 million in 2019 and is projected to grow at 7.31% CAGR over the forecast period to reach US $236.76 million by 2027. Fungal Keratitis segment represented US $21.58 million opportunity over 2019-2021 and estimated to create US $89.66 million opportunity in 2027 over 2021.

Keratoconus

Keratoconus segment was valued at US $49.98 million in 2019 and is projected to grow at 7.31% CAGR over the forecast period to reach US $94.28 million by 2027. Keratoconus segment represented US $8.59 million opportunity over 2019-2021 and estimated to create US $35.70 million opportunity in 2027 over 2021.

Other Diseases

Other Diseases segment was valued at US $46.35 million in 2019 and is projected to grow at 7.31% CAGR over the forecast period to reach US $87.43 million by 2027. Other Diseases segment represented US $7.97 million opportunity over 2019-2021 and estimated to create US $33.11 million opportunity in 2027 over 2021.

End-user

Introduction

In 2021, Hospitals segment has the highest revenue of US $196.95 million and is expected to grow at CAGR of 7.31% by 2027 Impact of COVID-19 on the End-User Market segment has highest cagr growth of 7.31%.

Impact of COVID-19 on the End-User Market

Impact of COVID-19 on the End-User Market segment was valued at US $135.39 million in 2019 and is projected to grow at 7.31% CAGR over the forecast period to reach US $255.39 million by 2027. Impact of COVID-19 on the End-User Market segment represented US $23.28 million opportunity over 2019-2021 and estimated to create US $96.72 million opportunity in 2027 over 2021.

Hospitals

Hospitals segment was valued at US $168.06 million in 2019 and is projected to grow at 7.31% CAGR over the forecast period to reach US $317.01 million by 2027. Hospitals segment represented US $28.89 million opportunity over 2019-2021 and estimated to create US $120.05 million opportunity in 2027 over 2021.

Specialty Clinics & Ambulatory Surgery Centers

Specialty Clinics & Ambulatory Surgery Centers segment was valued at US $82.67 million in 2019 and is projected to grow at 7.31% CAGR over the forecast period to reach US $155.95 million by 2027. Specialty Clinics & Ambulatory Surgery Centers segment represented US $14.21 million opportunity over 2019-2021 and estimated to create US $59.06 million opportunity in 2027 over 2021.

Region

Introduction

In 2021, North America segment has the highest revenue of US $196.79 million and is expected to grow at CAGR of 7.31% by 2027 North America segment has highest cagr growth of 7.31%.

North America

North America segment was valued at US $167.92 million in 2019 and is projected to grow at 7.31% CAGR over the forecast period to reach US $316.74 million by 2027. North America segment represented US $28.87 million opportunity over 2019-2021 and estimated to create US $119.96 million opportunity in 2027 over 2021.

Europe

Europe segment was valued at US $101.01 million in 2019 and is projected to grow at 7.31% CAGR over the forecast period to reach US $190.54 million by 2027. Europe segment represented US $17.37 million opportunity over 2019-2021 and estimated to create US $72.16 million opportunity in 2027 over 2021.

Asia-Pacific

Asia-Pacific segment was valued at US $56.35 million in 2019 and is projected to grow at 7.31% CAGR over the forecast period to reach US $106.30 million by 2027. Asia-Pacific segment represented US $9.69 million opportunity over 2019-2021 and estimated to create US $40.26 million opportunity in 2027 over 2021.

Latin America

Latin America segment was valued at US $35.92 million in 2019 and is projected to grow at 7.31% CAGR over the forecast period to reach US $67.76 million by 2027. Latin America segment represented US $6.18 million opportunity over 2019-2021 and estimated to create US $25.66 million opportunity in 2027 over 2021.

Middle East & Africa

Middle East & Africa segment was valued at US $24.92 million in 2019 and is projected to grow at 7.31% CAGR over the forecast period to reach US $47.00 million by 2027. Middle East & Africa segment represented US $4.28 million opportunity over 2019-2021 and estimated to create US $17.80 million opportunity in 2027 over 2021.